Successful management of an extreme example of neonatal hyperprostaglandin-E syndrome (Bartter's syndrome) with the new cyclooxygenase-2 inhibitor rofecoxib
| Autor: | Martin A. G. Lewin, Christoph H. Schneider, Frank Uhlemann, Robert Nossal, Nikolaus A. Haas, Volker Ocker, Martin Holder |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
medicine.medical_treatment
Critical Care and Intensive Care Medicine law.invention Lactones Refractory law medicine Humans Cyclooxygenase Inhibitors Sulfones Rofecoxib biology business.industry Infant Newborn Bartter Syndrome Intensive care unit Bartter's syndrome Anesthesia Pediatrics Perinatology and Child Health Failure to thrive biology.protein Vomiting Cyclooxygenase medicine.symptom business Central venous catheter medicine.drug |
| Zdroj: | Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. 4(2) |
| ISSN: | 1529-7535 |
| Popis: | Objective To describe the successful treatment of an unusual case of severe neonatal Bartter’s syndrome refractory to treatment with indomethacin. Design Case report, clinical. Setting Tertiary care intensive care unit. Patients A patient with neonatal hyperprostaglandin-E syndrome and excessive requirements of intravenous (via central venous catheter) water and salt supplementation, failure to thrive, vomiting, and massive growth retardation, despite adequate treatment with indomethacin. Main Result Four weeks after induction of the new cyclooxygenase-2 inhibitor rofecoxib, the patient was well, on full enteral feeds, thriving, and had gained 600 g in weight. A lower supplementary potassium, magnesium, and sodium intake was required. Reinstitution of indomethacin therapy resulted in severe deterioration, despite high indomethacin doses; symptoms improved again after rofecoxib administration. No side effects have been seen thus far. Conclusion This report shows that in selected patients with a severe form of neonatal Bartter’s syndrome, the new cyclooxygenase-2 inhibitor rofecoxib may control the clinical symptoms of hyperprostaglandin-E syndrome after ineffective indomethacin therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|